IGL Medical and Konsyl? Pharmaceuticals Partner to Bring SITZMARKS? to Israel

IGL Medical is pleased to announce that an exclusive agreement has been signed with Konsyl? Pharmaceuticals to distribute SITZMARKS? in Israel. SITZMARKS? is a safe, non-invasive diagnostic medical device tool for patients suffering from persistent constipation.

"The relaunch of SITZMARKS? will help doctors reach a better diagnosis and will improve the quality of life of our customers," says Moti Chehanover, IGL Medical managing director.

SITZMARKS? is a revolutionary diagnostic tool that helps doctors accurately diagnose chronic constipation. It is a simple, non-invasive test that can be done in the comfort of the patient's home. The test results are then sent to the doctor for review and diagnosis.

"Konsyl is excited to work with IGL as the exclusive distributor of SITZMARKS s in Israel," says Gary April , President of Konsyl Pharmaceuticals. "Persistent or functional constipation is on the rise worldwide, and SITZMARKS can help provide doctors with an important tool to determine next steps in the treatment of this chronic condition."

With the launch of SITZMARKS? in Israel, IGL Medical and Konsyl Pharmaceuticals are helping to improve the quality of life of those suffering from chronic constipation. This partnership will help to ensure that patients in Israel have access to the best possible diagnostic tools and treatments.

Konsyl? Pharmaceuticals has been committed to developing high-quality products for over 85 years, offering a variety of natural fiber products, dietary supplements, and unique medical devices for diagnosing constipation.